

2ND WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES

March 28-30, 2011

Hilton New York • New York, NY • USA

CONGRESS DIRECTOR
Francesco Rubino, MD



ADVANCE PROGRAM

www.wcidt.org

HOSTED BY




Weill Cornell Medical College

NewYork-Presbyterian Hospital
Weill Cornell Medical Center

FONDAZIONE
GIOVANNI LORENZINI
MILAN, ITALY



GIOVANNI LORENZINI
MEDICAL FOUNDATION
HOUSTON, TX, USA



2ND WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES



ENDORISING SOCIETIES

The 2nd World Congress on Interventional Therapies for Type 2 Diabetes is endorsed by the following organizations.



American Association of Clinical Endocrinologists



American Association of Endocrine Surgeons



THE AGA INSTITUTE
American Gastroenterological Association



American Society for Metabolic and Bariatric Surgery

Asociacion De Cirugia Bariatrica Y Metabolica De Guatemala



Asia Pacific, Metabolic & Bariatric Surgery Society



Asociacion Latinoamericana De Cirujanos Endoscopistas



Association for the Study of Obesity



Belgian Endocrine Society



Diabetes UK



Endocrine Society



European Association for Endoscopic Surgery



European Association for the Study of Diabetes

IFSO Sweden



Indian Association of Gastrointestinal Endo-Surgeons



International Atherosclerosis Society



International Federation for the Surgery of Obesity and Metabolic Disorders



Italian Society of Endocrinology



Japan Society for the Study of Obesity



National Obesity Forum

ENDORISING SOCIETIES

The 2nd World Congress on Interventional Therapies for Type 2 Diabetes is Endorsed by the Following Organizations.



Obesity & Metabolic Surgery Society of India



The Obesity Society



THE OBESITY SURGERY SOCIETY OF AUSTRALIA AND NEW ZEALAND

Obesity Surgery Society of Australia & New Zealand



The Philippine Society for Metabolic and Bariatric Surgery



Qatar Diabetes Association – Qatar Foundation



Sociedad Argentina de Diabetes



Sociedade Brasileira de Cirurgia Bariátrica e Metabólica



Sociedade Brasileira de Diabetes (SBD)



Sociedad de Cirujanos de Chile



Sociedad Española de Diabetes



Società Italiana dell'Obesità



Società Italiana di Chirurgia dell'Obesità e delle malattie metaboliche

Società Italiana di Diabetologia



Società Italiana per la Prevezione Cardiovascolare



Society for Endocrinology



Society of American Gastrointestinal and Endoscopic Surgeons




The Society for Surgery of the Alimentary Tract



Swiss Society for the Study of Morbid Obesity and Metabolic Disorders

This program is supported in name only by the American Heart Association's Councils on Basic Cardiovascular Sciences, Clinical Cardiology, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, Kidney in CV Disease, and High Blood Pressure Research. <http://www.heart.org/HEARTORG/>





2ND WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES

Scope

The World Congress on Interventional Therapies for Type 2 Diabetes is a comprehensive, multidisciplinary forum where leading international experts will conduct a critical review and discussion of the latest research findings on metabolic/bariatric surgery and novel interventional therapies for type 2 diabetes.

The signature design of this congress includes state-of-the art review lectures and debates among clinicians, scientists, and policy makers.

The overarching aim is to craft an agenda of research priorities and health policy initiatives relevant to the use and study of gastrointestinal interventions, with the ultimate goal of improving the treatment and understanding of diabetes and providing direction for treatments of curative intent.



Specific themes of the World Congress include:


- Epidemiology and economic impact of diabetes
- Latest research findings on interventional therapies for type 2 diabetes
- Current recommendations/guidelines for surgical treatment of diabetes
- Impact of interventional therapies on cardiovascular risk in diabetic patients
- Role of integrated surgical and medical approaches for diabetes (multimodality therapies)
- Novel technologies and gastrointestinal devices for diabetes
- Cost effectiveness of surgery as a treatment for diabetes
- Conventional paradigms vs. novel ideas on the etiology of diabetes and obesity: debate by leading scientists in the field
- Mechanisms of surgical control of diabetes and gastrointestinal targets for drug development



Who Should Attend?

This Congress is designed for professionals in the fields of endocrinology, diabetes, bariatric/metabolic surgery, cardiology, epidemiology, gastroenterology, internal medicine, family medicine, pharmacology, nutrition, basic science, and public health, as well as allied health professionals, policy makers, and scientists from the pharmaceutical and medical device industries.

Register now at www.wcidt.org



Congress Program Committee

CONGRESS DIRECTOR

FRANCESCO RUBINO, MD
Weill Cornell Medical College
New York, NY, USA

PROGRAM COMMITTEE CHAIRS and CO-CHAIRS

CLINICAL TRACK

Chair

HAROLD E. LEBOVITZ, MD
State University of New York,
Health Science Center
Brooklyn, NY, USA

Co-Chair

PHILIP SCHAUER, MD
Cleveland Clinic
Cleveland, OH, USA

RESEARCH TRACK

Chair

DAVID E. CUMMINGS, MD
Diabetes Endocrinology
Research Center
University of Washington
Seattle, WA, USA

Co-Chair

LEE M. KAPLAN, MD, PhD
Harvard Medical School
Boston, MA, USA

POLICY TRACK

Chair

PAUL ZIMMET, MD, PhD
Baker IDI Heart and Diabetes
Institute
Melbourne, Australia

Co-Chair

DAVID FLUM, MD, MPH
University of Washington
Seattle, WA, USA

PROGRAM COMMITTEE MEMBERS

DOMENICO ACCILI, MD

Columbia University Medical Center
New York, NY, USA

LOUIS ARONNE, MD

Weill Cornell Medical College
New York, NY, USA

RICARDO V. COHEN, MD

The Center for the Surgical Treatment
of Obesity and Metabolic Disorders
Hospital Oswaldo Cruz
Sao Paulo, Brazil

JOHN DIXON, MBBS, PhD

Baker IDI Heart and Diabetes Institute
Melbourne, Australia

ROBIN S. GOLAND, MD

Columbia University College of
Physicians & Surgeons
New York, NY, USA

ALLISON B. GOLDFINE, MD

Joslin Diabetes Center
Boston, MA, USA

M. SUE KIRKMAN, MD

American Diabetes Association
Alexandria, VA, USA

SAMUEL KLEIN, MD

Washington University School of Medicine
St. Louis, MO, USA

RUDOLPH L. LEIBEL, MD

Columbia University Medical Center
New York, NY, USA

CAREL W. LE ROUX, MRCP, PhD

Imperial College
London, UK

TIMOTHY E. MCGRAW, PhD

Weill Cornell Medical College
New York, NY, USA

JEFFREY I. MECHANICK, MD


American Association of Clinical
Endocrinologists
New York, NY, USA

JESSE ROTH, MD

Albert Einstein College of Medicine
Manhasset, NY, USA

ADVISORY COMMITTEE MEMBERS

Linda Cann, MEd (Alexandria, VA, USA), Ricardo V. Cohen, MD (Sao Paulo, Brazil), David E. Cummings, MD (Seattle, WA, USA), Antonio M. Gotto, JR., MD, DPhil (New York, NY, USA), Lee M. Kaplan, MD, PhD (Boston, MA, USA), M. Sue Kirkman, MD (Alexandria, VA, USA), Harold E. Lebovitz, MD (Brooklyn, NY, USA), Fabrizio Michelassi, MD (New York, NY, USA), Alfons Pomp, MD (New York, NY, USA), Philip Schauer, MD (Cleveland, OH, USA), Paul Zimmet, MD, PhD (Melbourne, Australia).



2ND WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES



DIABETES
CURRENTLY AFFECTS
246 MILLION PEOPLE
WORLDWIDE,
ACCORDING TO THE
INTERNATIONAL
DIABETES
FEDERATION (IDF).

DURING THE
WORLD CONGRESS,
THE IDF
WILL ANNOUNCE ITS
FIRST POSITION
STATEMENT ON
METABOLIC/BARIATRIC
SURGERY AND GI
INTERVENTIONS
FOR THE
TREATMENT OF
DIABETES.

Program Format

Plenary Sessions

There will be three Congress tracks: clinical, research, and policy. Each track has multiple sessions. The program of each Congress session includes state of the art lectures providing a review of available data. The lectures will be followed by an interactive expert panel discussion as well as Q&A time with the audience. The panel debates are the signature feature of this congress and will provide an opportunity for interactive discussions.

Breakout Sessions *(Tuesday evening, March 29th)*

The Faculty and audience will divide into separate rooms for each of the three tracks. Faculty designates will lead with a prepared selection of evidence based topics and potential conclusions that are designed to capture the consensus of session participants. Each of these breakout sessions will last for 2 hours.

Conclusive Plenary Session *(Wednesday, March 30th)*


A summary of the conclusions of the three breakout sessions will be presented by a Faculty representative in the final plenary session of the Congress. An interactive voting system will be used to verify which conclusions obtain the greatest enthusiasm and support from the participants. This process will ultimately generate an executive summary of the main Congress outcomes.

After the Congress

Shortly after the New York meeting, a dedicated Writing Committee will draft a consensus document detailing the outcomes of the Conclusive Plenary Session. Its aim and content is not to generate new clinical guidelines, but to highlight the most important messages from the World Congress. Inevitably, it will indicate areas of research that should receive priority and call to action appropriate policy changes. This will be submitted to a relevant medical journal for publication as a white paper.



THE GI TRACT IS AN IMPORTANT ENDOCRINE ORGAN. IT COMMUNICATES WITH PERIPHERAL ORGANS REGULATING APPETITE/SATIETY AND INSULIN SECRETION. THE MECHANISMS OF ACTION OF GI METABOLIC SURGERY AND THE POTENTIAL ROLE OF THE GUT IN OBESITY/DIABETES WILL BE DISCUSSED IN THIS CONGRESS.



Distinguished Faculty

DOMENICO ACCILI, MD

Columbia University Medical Center
New York, NY, USA

TED D. ADAMS, PhD, MPH

University of Utah School of Medicine
Health & Fitness Institute, LDS Hospital
Salt Lake City, UT, USA

**K. GEORGE ALBERTI, MA, DPhil,
BM BCh**

Imperial College London
London, UK

HANAN AL KUWARI, PhD

Hamad Medical Corporation
Doha, Qatar

STEPHANIE A. AMIEL, MD

Kings College London
London, UK

CAROLINE M. APOVIAN, MD

Boston University School of Medicine
Boston, MA, USA

LOUIS ARONNE, MD

Weill Cornell Medical College
New York, NY, USA

NICOLA BASSO, MD

Università degli Studi di Roma "La
Sapienza"
Rome, Italy

RICHARD N. BERGMAN, PhD

University of Southern California
Los Angeles, CA, USA

ZACHARY T. BLOOMGARDEN, MD

Mount Sinai School of Medicine
New York, NY, USA

STACY A. BRETHER, MD

Cleveland Clinic
Cleveland, OH, USA

MICHAEL S. BROWN, MD

University of Texas Southwestern
Medical Center
Dallas, TX, USA

HENRY BUCHWALD, MD, PhD

University of Minnesota Medical School
Minneapolis, MN, USA

PRADEEP CHOWBEY, MS

Institute of Minimal Access, Metabolic
& Bariatric Surgery
Max Healthcare
New Delhi, India

RICARDO V. COHEN, MD

The Center for the Surgical Treatment
of Obesity and Metabolic Disorders
Hospital Oswaldo Cruz
Sao Paulo, Brazil

DAVID E. CUMMINGS, MD

Diabetes Endocrinology Research
Center
University of Washington
Seattle, WA, USA

TAMARA DARSOW, PhD

American Diabetes Association
Alexandria, VA, USA

ARA DARZI, MD

Imperial College London
London, UK

RALPH DEFONZO, MD

School of Medicine, UT Health Science
Center, San Antonio
San Antonio, TX, USA

STEFANO DEL PRATO, MD

University of Pisa
Pisa, Italy

AUREO DE PAULA, MD

Hospital de Especialidades
Goiania, Brazil

JOHN DIXON, MBBS, PhD

Baker IDI Heart and Diabetes Institute
Melbourne, Australia

ROBERT H. ECKEL, MD

University of Colorado Denver
Anschutz Medical Campus
Aurora, CO, USA

ELE FERRANNINI, MD

University of Pisa
Pisa, Italy

DAVID FLUM, MD, MPH

University of Washington
Seattle, WA, USA

JOHN FUNDER, MD, PhD

Prince Henry's Institute
Clayton, VIC, Australia

MICHEL GAGNER, MD, PhD

Herbert Wertheim College of Medicine
Florida International University
Miami, FL, USA

MANOEL GALVAO NETO, MD

Gastro Obeso Center
São Paulo, Brazil

ROBIN S. GOLAND, MD

Columbia University College of
Physicians & Surgeons
New York, NY, USA

ALLISON B. GOLDFINE, MD

Joslin Diabetes Center
Boston, MA, USA

JOSEPH L. GOLDSTEIN, MD

University of Texas Southwestern
Medical Center
Dallas, TX, USA

ANTONIO M GOTTO, JR., MD, DPhil

Weill Cornell Medical College
New York, NY, USA

JAN WILLEM M. GREVE, MD

Atrium Medical Center Parkstad
Heerlen, The Netherlands

YUSAKE HADA, MD

Tokyo University School of Medicine
Tokyo, Japan

BJØRN M. HOFMANN, MSC, PhD


Center for Medical Ethics
University of Oslo and University
College of Gjøvik
Oslo and Gjøvik, Norway

JENS JUUL HOLST, MD

Copenhagen University
Copenhagen, Denmark

LINONG JI, MD

Peking University People's Hospital
Beijing, China



Distinguished Faculty

SHASHANK R. JOSHI, MD, DM

Grant Medical College and Sir JJ Group of Hospitals
Mumbai, India

STEVEN E. KAHN, MB, ChB

VA Puget Sound Health Care System and University of Washington
Seattle, WA, USA

LEE M. KAPLAN, MD, PhD

Harvard Medical School
Boston, MA, USA

CATHERINE KEATING, MPH

Deakin University
Melbourne, Australia

M. SUE KIRKMAN, MD

American Diabetes Association
Alexandria, VA, USA

SAMUEL KLEIN, MD

Washington University School of Medicine
St. Louis, MO, USA

JUDITH KORNER, MD, PhD

Columbia University College of Physicians and Surgeons
New York, NY, USA

BLANDINE B. LAFERRERE, MD

New York Obesity Nutrition Research Center
Columbia University College of Physicians and Surgeons
New York, NY, USA

HAROLD E. LEBOVITZ, MD

State University of New York, Health Science Center
Brooklyn, NY, USA

FRANK LEFEVRE, MD

Northwestern University Feinberg School of Medicine
BCBSA Technology Evaluation Center
Chicago, IL, USA

RUDOLPH L. LEIBEL, MD

Columbia University Medical Center
New York, NY, USA

CAREL W. LE ROUX, MRCP, PhD

Imperial College
London, UK

RUTH E. LEY, PhD

Cornell University
Ithaca, NY, USA

RUI LI, PhD

Centers for Disease Control and Prevention
Atlanta, GA, USA

TIMOTHY E. MCGRAW, PhD

Weill Cornell Medical College
New York, NY, USA

JEFFREY I. MECHANICK, MD

American Association of Clinical Endocrinologists
New York, NY, USA

GELTRUDE MINGRONE, MD, PhD

Universita' Cattolica del S. Cuore
Rome, Italy

F. XAVIER PI-SUNYER, MD

Columbia University College of Physicians and Surgeons
New York, NY, USA

ALFONS POMP, MD

Weill Cornell Medical College
New York, NY, USA

WALTER PORIES, MD

East Carolina University, Brody School of Medicine
Greenville, NC, USA

JESSE ROTH, MD

Albert Einstein College of Medicine, Yeshiva University
Feinstein Institute for Medical Research
Manhasset, NY, USA

FRANCESCO RUBINO, MD

Weill Cornell Medical College
New York, NY, USA

MOH'D. FATHY SAOUD, PhD

Qatar Foundation
Doha, Qatar

PHILIP SCHAUER, MD

Cleveland Clinic
Cleveland, OH, USA

GARY J. SCHWARTZ, PhD

Albert Einstein College of Medicine
Bronx, NY, USA

RANDY J. SEELEY, PhD

Metabolic Diseases Institute
University of Cincinnati
Cincinnati, OH, USA

HARVEY J. SUGERMAN, MD

Virginia Commonwealth University
Richmond, VA, USA

GERALD SHULMAN, MD, PhD

Howard Hughes Medical Institute
Yale School of Medicine
New Haven, CT, USA

LARS SJÖSTRÖM, MD, PhD

Institute of Internal Medicine
Sahlgrenska University Hospital
Göteborg, Sweden

MYRLENE STATEN, MD

NIDDK, National Institutes of Health
Bethesda, MD, USA

SEAN D. SULLIVAN, PhD

School of Pharmacy, University of Washington
Seattle, WA, USA

TESS VAN DER MERWE, MBChB, PhD

University of Pretoria
Pretoria, South Africa

BRUCE M. WOLFE, MD

Oregon Health & Science University
Portland, OR, USA

CAROL H. WYSHAM, MD

University of Washington School of Medicine
Seattle, WA, USA

JAMES YOUNG, MD

Cleveland Clinic
Cleveland, OH, USA

PAUL ZIMMET, MD, PhD

Baker IDI Heart and Diabetes Institute
Melbourne, Australia

Scientific Program

MONDAY, MARCH 28, 2011

8:00 am - 8:20 am **Opening Ceremony**

8:20 am - 8:35 am **Introduction of the World Congress: Scope and Methods**
F. Rubino (New York, NY, USA)

CLINICAL TRACK SESSION I | 8:35 am - 10:50 am

Clinical Outcomes of Conventional and Surgical Treatments for T2DM

Chairs: W. Pories (Greenville, NC, USA) • H.E. Lebovitz (Brooklyn, NY, USA)

8:35 am - 8:55 am **Glycemic and metabolic control with current pharmacologic treatments**
S. Del Prato (Pisa, Italy)

8:55 am - 9:15 am **Glycemic and metabolic outcomes with bariatric/metabolic surgery: overview**
P. Schauer (Cleveland, OH, USA)

9:15 am - 9:30 am **Long-term prevention and remission of diabetes after bariatric surgery in the SOS study**
L. Sjöström (Göteborg, Sweden)

9:30 am - 9:45 am **Safety profiles of pharmaceutical approaches**
H.E. Lebovitz (Brooklyn, NY, USA)

9:45 am - 10:00 am **Safety profiles of surgical approaches: short and long term**
B.M. Wolfe (Portland, OR, USA)

10:00 am - 10:50 am **Panel Discussion**
Panelists: S.A. Amiel (London, UK), Z.T. Bloomgarden (New York, NY, USA), J. Dixon (Melbourne, Australia), A. Pomp (New York, NY, USA), H. Buchwald (Minneapolis, MN, USA), A.B. Goldfine (Boston, MA, USA), K.G. Alberti (London, UK), J.I. Mechanick (New York, NY, USA), X. Pi-Sunyer (New York, NY, USA)

10:50 am - 11:10 am COFFEE BREAK

POLICY TRACK SESSION I | 11:10 am - 12:30 pm

The International Diabetes Federation (IDF) Position Statement on Interventional Treatments of Type 2 Diabetes

Chairs: J. Dixon (Melbourne, Australia) • K.G. Alberti (London, UK)

11:10 am - 11:20 am **Existing guidelines for surgical treatment of obesity and diabetes (NIH, DSS, ADA)**
L.M. Kaplan (Boston, MA, USA)

11:20 am - 11:40 am **The IDF position statement on interventional therapies for type 2 diabetes**
P. Zimmet (Melbourne, Australia)

11:40 am - 12:30 pm **Panel Discussion**
Panelists: C. Wysham (ADA) (Seattle, WA, USA), J.I. Mechanick (AACE) (New York, NY, USA), S.A. Amiel (Diabetes UK) (London, UK), X. Pi-Sunyer (NHLBI) (New York, NY, USA), A.M. Gotto (New York, NY, USA), F. Rubino (New York, NY, USA), R.H. Eckel (Aurora, CO, USA)

12:30 pm - 1:30 pm LUNCH BREAK

Scientific Program

MONDAY, MARCH 28, 2011 (continued)

CLINICAL TRACK SESSION II | 1:30 pm - 3:00 pm

CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical Therapy

Chairs: A.M. Gotto (*New York, NY, USA*) • K.G. Alberti (*London, UK*)

1:30 pm - 1:50 pm	CV risk, CVD and diabetes-related mortality: impact of pharmacologic approaches R.H. Eckel (<i>Aurora, CO, USA</i>)
1:50 pm - 2:05 pm	Long-term (20 years) impact of bariatric surgery on CV risk and CVD: an update from the SOS study L. Sjöström (<i>Göteborg, Sweden</i>)
2:05 pm - 2:15 pm	The impact of bariatric/metabolic surgery on CV risk and long-term survival T.D. Adams (<i>Salt Lake City, UT, USA</i>)
2:15 pm - 3:00 pm	Panel Discussion Panelists: R. DeFronzo (<i>San Antonio, TX, USA</i>), E. Ferrannini (<i>Pisa, Italy</i>), S.R. Joshi (<i>Mumbai, India</i>), S.E. Kahn (<i>Seattle, WA, USA</i>), J. Young (<i>Cleveland, OH, USA</i>), H.J. Sugerman (<i>Richmond, VA, USA</i>), W. Pories (<i>Greenville, NC, USA</i>)
3:00 pm - 3:20 pm	COFFEE BREAK

CLINICAL TRACK SESSION III | 3:20 pm - 5:45 pm

Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative Management

Chairs: R.S. Goland (*New York, NY, USA*) • L. Aronne (*New York, NY, USA*)

3:20 pm - 3:35 pm	Predicting factors of diabetes control/reasonable criteria for surgical indication J. Korner (<i>New York, NY, USA</i>)
3:35 pm - 3:50 pm	Preoperative management of diabetic patients C.M. Apovian (<i>Boston, MA, USA</i>)
3:50 pm - 4:05 pm	Which surgical procedure is best? Summary of available evidence from comparative clinical studies in high and low BMI patients H.J. Sugerman (<i>Richmond, VA, USA</i>)
4:05 pm - 4:40 pm	Panel Discussion Panelists: H.E. Lebovitz (<i>Brooklyn, NY, USA</i>), S.R. Joshi (<i>Mumbai, India</i>), J.I. Mechanick (<i>New York, NY, USA</i>), J. Dixon (<i>Melbourne, Australia</i>), M. Gagner (<i>Montreal, QC, Canada</i>), R.V. Cohen (<i>Sao Paulo, Brazil</i>)
4:40 pm - 4:55 pm	Postoperative management of obese and diabetic patients; the role of integrated/multimodality therapies L. Aronne (<i>New York, NY, USA</i>)
4:55 pm - 5:15 pm	A rational and physiologic approach to the management of diabetes after surgery R. DeFronzo (<i>San Antonio, TX, USA</i>)
5:15 pm - 5:45 pm	Panel Discussion Panelists: C. Wysham (<i>Seattle, WA, USA</i>), S.E. Kahn (<i>Seattle, WA, USA</i>), R.N. Bergman (<i>Los Angeles, CA, USA</i>), L. Ji (<i>Beijing, China</i>), S. Del Prato (<i>Pisa, Italy</i>)
5:45 pm - 6:45 pm	POSTER SESSION
8:00 pm	WELCOME RECEPTION

Scientific Program

TUESDAY, MARCH 29, 2011

RESEARCH TRACK SESSION I | 7:30 am - 9:40 am

Mechanisms of Action of Surgery

Chairs: L.M. Kaplan (*Boston, MA, USA*) • S.E. Kahn (*Seattle, WA, USA*)

- 7:30 am - 7:45 am **Mechanisms of Weight Loss: beyond restriction and malabsorption**
R.J. Seeley (*Cincinnati, OH, USA*)
- 7:45 am - 8:00 am **Effect of GI surgery on insulin secretion/sensitivity**
S. Klein (*St. Louis, MO, USA*)
- 8:00 am - 8:15 am **Effects of GI surgery on food choices and energy expenditure**
C.W. Le Roux (*London, UK*)
- 8:15 am - 8:30 am **Effects of GI surgery on glucose homeostasis**
J.J. Holst (*København, Denmark*)
- 8:30 am - 9:00 am **Debate: Diabetes control by GI surgery is explained by weight-independent mechanisms**
8:30 am - 8:45 am Yes: D.E. Cummings (*Seattle, WA, USA*)
8:45 am - 9:00 am No: E. Ferrannini (*Pisa, Italy*)
- 9:00 am - 9:40 am **Panel Discussion: Weight independent mechanisms of diabetes control: weighing the evidence**
Panelists: J. Korner (*New York, NY, USA*), G. Mingrone (*Rome, Italy*), R.N. Bergman (*Los Angeles, CA, USA*), R. DeFronzo (*San Antonio, TX, USA*), B.B. LaFerrere (*New York, NY, USA*), G.J. Schwartz (*New York, NY, USA*)

RESEARCH TRACK SESSION II | 9:40 am - 11:10 am

Novel Experimental Approaches for Diabetes/Obesity

Chairs: H. Buchwald (*Minneapolis, MN, USA*) • S. Klein (*St. Louis, MO, USA*)

- 9:40 am - 9:55 am **Novel GI surgical procedures (DJB and Ileal Interposition: alone and with associated sleeve gastrectomy)**
R.V. Cohen (*Sao Paulo, Brazil*)
- 9:55 am - 10:10 am **Endoluminal procedures for obesity/diabetes**
S.A. Brethauer (*Cleveland, OH, USA*)
- 10:10 am - 10:25am **Endoluminal devices for obesity/diabetes**
L.M. Kaplan (*Boston, MA, USA*)
- 10:25 am - 10:40 am **Pacing/GI electric stimulation for diabetes**
H.E. Lebovitz (*Brooklyn, NY, USA*)
- 10:40 am - 11:10 am **Panel Discussion**
Panelists: J. Greve, (*Heerleen, Netherlands*), M. Galvao Neto (*Sao Paulo, Brazil*), A. De Paula (*Goiania, Brazil*), W. Piores (*Greenville, NC, USA*), J. Funder (*Clayton, Australia*), S.R. Joshi (*Mumbai, India*)
-
- 11:10 am - 11:30 am COFFEE BREAK

Scientific Program

TUESDAY, MARCH 29, 2011 (continued)

RESEARCH TRACK SESSION III | 11:30 am - 1:00 pm

Defining Priorities for Clinical Research in Metabolic/Diabetes Surgery

Chairs: A.B. Goldfine (Boston, MA, USA) • J. Roth (Manhasset, NY, USA)

- 11:30 am - 11:45 am **Clinical trials in diabetes surgery: overview of ongoing trials; challenges for study design, practical issues in surgical trials**
A.B. Goldfine (Boston, MA, USA)
- 11:45 am - 12:00 pm **Clinical trials in diabetes surgery: ethical aspects**
B.M. Hofmann (Oslo, Norway)
- 12:00 pm - 12:15 pm **Advantages and disadvantages of each design, multisite vs consortium model for large clinical trials**
F. Rubino (New York, NY, USA)
- 12:15 pm - 1:00 pm **Panel Discussion: Priorities for clinical research in diabetes surgery; costs/funding, ethical aspects**
Panelists: P. Schauer (Cleveland, OH, USA), R. DeFronzo (San Antonio, TX, USA), J. Korner (New York, NY, USA), L. Sjöström (Göteborg, Sweden), M. Staten (NIH/NIDDK) (Bethesda, MD, USA), F. Saoud (Qatar Foundation) (Doha, Qatar), T. Darsaw (ADA) (Alexandria, VA, USA)
- 1:00 pm - 2:00 pm LUNCH BREAK

POLICY TRACK SESSION II | 2:00 pm - 3:00 pm

Global Burden of Diabetes and Resource Availability for Interventional Approaches

Chairs: P. Zimmet (Melbourne, Australia) • P. Chowbey (New Delhi, India)

- 2:00 pm - 2:15 pm **The global epidemiology of diabetes**
P. Zimmet (Melbourne, Australia)
- 2:15 pm - 2:30 pm **The global costs of diabetes**
R. Li (CDC) (Atlanta, GA, USA)
- 2:30 pm - 3:00 pm **Panel Discussion: Specific regional challenges for diabetes prevention and treatment**
Panelists: L. Ji (Beijing, China), J. Funder (Clayton, Australia), T. Van Der Merwe (Pretoria, South Africa), A. Darzi (London, UK), H. Al Kuwari (Doha, Qatar)

POLICY TRACK SESSION III | 3:00 pm - 4:30 pm

Cost Effectiveness of Diabetes Surgery: Implications for Public and Private Health Insurance

Chairs: A. Darzi (London, UK) • D. Flum (Seattle, WA, USA)

- 3:00 pm - 3:15 pm **Review of what we know about cost-effectiveness of bariatric surgery with special regard to patients with diabetes**
C. Keating (Burwood, Australia)
- 3:15 pm - 3:30 pm **How governments consider evidence on cost-effectiveness**
S.D. Sullivan (Seattle, WA, USA)
- 3:30 pm - 3:45 pm **How payers consider the evidence of cost and effectiveness**
F. Lefevre (Chicago, IL, USA)
- 3:45 pm - 4:30 pm **Panel Discussion: Simply cost-effective? Reconciling cost-evaluations related to diabetes interventions**
Panelists: R. Li (CDC) (Atlanta, GA, USA), C. Keating (Burwood, Australia), S.D. Sullivan (Seattle, WA, USA), F. Lefevre (Chicago, IL, USA)

Scientific Program

TUESDAY, MARCH 29, 2011 (continued)

4:30 pm - 4:50 pm COFFEE BREAK

BREAKOUT SESSIONS AND WORKSHOPS | 4:50 pm - 6:50 pm

4:50 pm - 6:50 pm **Break-out Sessions for Review of Evidence, Interacting Discussion and Preparation of Executive Summary**

Session A: CLINICAL TRACK

Defining appropriate surgical candidates and good clinical practice for perioperative management and post-operative follow-up

Chairs: H.E. Lebovitz (*Brooklyn, NY, USA*) • P. Schauer (*Cleveland, OH, USA*)

Program: To be announced

Session B: RESEARCH TRACK

Defining clinical research priorities

Chairs: D.E. Cummings (*Seattle, WA, USA*) • L.M. Kaplan (*Boston, MA, USA*)

Program: To be announced

Session C: POLICY TRACK

Chairs: P. Zimmet (*Melbourne, Australia*) • D. Flum (*Seattle, WA, USA*)

Workshop A: "Creating a pathway to reconcile professional guidelines"

4:50 pm - 5:00 pm **Summary lecture**

J.B. Dixon (*Melbourne, Australia*)

5:00 pm - 5:40 pm **Panel Discussion/Round Table with official representatives of the following organizations:**
NHLBI Obesity Guidelines (X. Pi-Sunyer), ADA (C. Wysham), AACE (J.I. Mechanick), ASMBS (B. Wolfe), TOS (C.M. Apovian), SBCBM (R.V. Cohen), SICOB (N. Basso)

5:40 pm - 5:50 pm **Interactive Polls**

Workshop B: "Payer perspectives: creating a pathway for policymakers and payers to reconcile approaches"

5:50 pm - 6:00 pm **Summary lecture:**

D. Flum (*Seattle, WA, USA*)

6:00 pm - 6:40 pm **Panel Discussion/Round Table**

F. Lefevre, (*Chicago, IL, USA*), S.D. Sullivan, (*Seattle, WA, USA*), A. Darzi, (*London, UK*), J. Funder, (*Clayton, Australia*), Y. Hada, (*Tokyo, Japan*), L. Ji, (*Beijing, China*), C. Keating, (*Buswood, Australia*), T. Van Der Merwe, (*Pretoria, South Africa*), H. Al Kuwari (*Doha, Qatar*)

6:40 pm - 6:50 pm **Interactive Polls**

Scientific Program

WEDNESDAY, MARCH 30, 2011

KEYNOTE LECTURE | 8:00 am - 9:00 am

8:00 am - 9:00 am **Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis**

M.S. Brown (*Dallas, TX, USA*)

J.L. Goldstein (*Dallas, TX, USA*)

The Nobel Prize in Physiology or Medicine 1985 was awarded jointly to Michael S. Brown and Joseph L. Goldstein "for their discoveries concerning the regulation of cholesterol metabolism".

RESEARCH TRACK SESSION IV | 9:00 am - 10:40 am

The role of the gut in the physiology and pathophysiology of obesity and diabetes

Chairs: T.E. McGraw (*New York, NY, USA*) • D. Accilli (*New York, NY, USA*)

- 9:00 am - 9:20 am **Conventional paradigm of the pathophysiology of obesity**
R.L. Leibel (*New York, NY, USA*)
- 9:20 am - 9:40 am **Conventional paradigm of the pathophysiology of diabetes**
R.N. Bergman (*Los Angeles, CA, USA*)
- 9:40 am - 10:00 am **The physiologic role of the gut in energy and glucose homeostasis**
J.J. Holst (*Copenhagen, Denmark*)
- 10:00 am - 10:20 am **Impaired GI physiology in individuals with diabetes/obesity**
D.E. Cummings (*Seattle, WA, USA*)
- 10:20 am - 10:40 am **The role of intestinal microbiota in insulin resistance, obesity/diabetes**
R.E. Ley (*Ithaca, NY, USA*)
-
- 10:40 am - 11:00 am COFFEE BREAK

PANEL DISCUSSION | 11:00 am - 12:00 pm

The GI tract: could it be the missing link between obesity and diabetes?

- 11:00 am - 11:05 am **Introduction**
F. Rubino (*New York, NY, USA*)
- 11:05 am - 12:00 pm **Panel Discussion**
M.S. Brown (*Dallas, TX, USA*), J.L. Goldstein (*Dallas, TX, USA*), G. Shulman (*New Haven, CT, USA*),
S. Klein (*Cincinnati, OH, USA*), R. DeFronzo (*San Antonio, TX, USA*), S.E. Kahn (*Seattle, WA, USA*),
J. Roth (*Manhasset, NY, USA*), L.M. Kaplan (*Boston, MA, USA*)

Scientific Program

WEDNESDAY, MARCH 30, 2011 (continued)

EXECUTIVE SUMMARIES/TAKE HOME MESSAGE		12:00 pm - 1:15 pm
Presentation of executive summaries and conclusions Chairs: M. Sue Kirkman (<i>Alexandria, VA, USA</i>) • W. Pories (<i>Greenville, NC, USA</i>)		
12:00 pm - 12:12 pm	Clinical Practice H.E. Lebovitz (<i>Brooklyn, NY, USA</i>)	
12:12 pm - 12:24 pm	Priorities for Clinical Research D.E. Cummings (<i>Seattle, WA, USA</i>)	
12:24 pm - 12:36 pm	Reconciling Guidelines P. Zimmet (<i>Melbourne, Australia</i>)	
12:36 pm - 12:48 pm	Public Health Policies D. Flum (<i>Seattle, WA, USA</i>)	
12:48 pm - 1:00 pm	The evolving paradigm of diabetes pathogenesis J. Roth (<i>Manhasset, NY, USA</i>)	
1:00 pm - 1:15 pm	INTERACTIVE OPINION POLLS	
1:15 pm - 1:20 pm	CLOSING REMARKS	

Registration & Accommodations

Congress Registration is now open! Register online at www.wcidt.org

The Congress registration fee includes: abstract book/final program and admission to all scientific sessions, exhibits, poster sessions, breakfasts, and coffee breaks. Registration rates for the 2nd World Congress on Interventional Therapies for Type 2 Diabetes are as follows. All registration fees are in US dollars.

Register by March 4th to save!

Registration fees:	By Mar 4, 2011	After Mar 4, 2011
Physicians and Scientists	\$590	\$680
Members of Endorsing/Sponsoring Societies*	\$490	\$580
Medical Students/Residents*	\$300	\$350
Allied Health Professionals*	\$360	\$420
Welcome Reception	\$85	\$125

* Must provide proof of status to receive reduced rate.




The 2nd World Congress on Interventional Therapies for Type 2 Diabetes will take place at:

Hilton New York

1335 Avenue of the Americas
New York, New York, USA 10019
Tel: 1-212-586-7000

For additional information about the Hilton New York, visit <http://wcidt.org/hotel-travel-information/>



Make Your Reservation

Make your hotel reservation for the Congress online at www.wcidt.org


The Congress has negotiated **special reduced rates** for Congress attendees.

Rates: \$219.00 per night Single/Double*

The Congress room rate is valid through **Sunday, February 20, 2011** or until rooms are sold out.

For group reservations of 10 or more room nights, please contact the Congress Office at wcidt@gomeeting.com or by phone at +1.410.571.0590.

* Rate does not include New York city, state and occupancy tax of approximately 19.8% (total cost per night: \$262.47). Please note that the Congress room block is limited and may fill before the deadline. Attendees are encouraged to book their hotel room early to avoid disappointment.



2nd World Congress on Interventional Therapies for Type 2 Diabetes
ATTENDEE ADVANCE REGISTRATION FORM (Page 1 of 2)
March 28-30, 2011 – Hilton New York, New York, NY USA

Return this form to address below or fax to +1 303 530 2691.

SECTION 1: ATTENDEE INFORMATION

First Name, Middle Name, Last Name _____

First Name on Badge (if different from above) _____

Job Title _____

Company/Organization/Institution _____

Mailing Address _____

City _____ State/Province _____ Zip/Postal Code _____

Country _____ Phone _____ Fax _____

Email Address _____

Degree: MD MD/PhD MSc PhD DO Other, please specify _____

1) Specialty: Please indicate primary and secondary specialty, using a "1" and "2" in the fields below.

- | | |
|--|---|
| <input type="checkbox"/> Endocrinology | <input type="checkbox"/> Nutrition |
| <input type="checkbox"/> Diabetology | <input type="checkbox"/> Pharmacology |
| <input type="checkbox"/> Metabolic/Bariatric Surgery | <input type="checkbox"/> Basic Science |
| <input type="checkbox"/> Cardiology | <input type="checkbox"/> Public Health |
| <input type="checkbox"/> Epidemiology | <input type="checkbox"/> Allied Health |
| <input type="checkbox"/> Gastroenterology | <input type="checkbox"/> Policy |
| <input type="checkbox"/> Internal Medicine | <input type="checkbox"/> Pharmaceutical/Medical Device Industry |
| <input type="checkbox"/> Family Medicine | <input type="checkbox"/> Other, please specify _____ |

2) How did you hear about this event?

- | | |
|--|---|
| <input type="checkbox"/> Email Mail | <input type="checkbox"/> Word of Mouth |
| <input type="checkbox"/> Mail/Postcard | <input type="checkbox"/> Conference Website |
| <input type="checkbox"/> Advertisement at another conference | <input type="checkbox"/> Other _____ |

3) If you are a student, Post Doc, Resident or Intern, please enter your information below completely:

Director's Name _____ Director's Facility _____


Program Director's Email _____

4) Special Needs

A) Please indicate any serious dietary allergies below (if none, leave blank). *We will make every effort to incorporate a range of dietary preferences into coffee breaks and reception functions, but please note that due to the large number of attendees, individual preferences cannot be accommodated.*

B) I require accommodations for my:

- | |
|--|
| <input type="checkbox"/> Wheelchair or other mobility impairment |
| <input type="checkbox"/> Hearing Impairment |
| <input type="checkbox"/> Other, please specify: _____ |



2nd World Congress on Interventional Therapies for Type 2 Diabetes ATTENDEE ADVANCE REGISTRATION FORM (Page 2 of 2)

SECTION 2: REGISTRATION FEES

	11-Jan-11 to 4-Mar-11	After 4-Mar-11	Amount
Clinicians and Scientists	<input type="checkbox"/> \$590	<input type="checkbox"/> \$680	\$ _____
Members of Endorsing/Sponsoring Societies*	<input type="checkbox"/> \$490	<input type="checkbox"/> \$580	\$ _____
Medical Students/Residents/Fellows*	<input type="checkbox"/> \$300	<input type="checkbox"/> \$350	\$ _____
Allied Health Professionals*	<input type="checkbox"/> \$360	<input type="checkbox"/> \$420	\$ _____
Welcome Reception	<input type="checkbox"/> \$85	<input type="checkbox"/> \$125	\$ _____

*If you have registered as an Endorsing/Sponsoring Member Societies or Medical Student/Resident, proof of status must accompany this registration form to receive the special rate. Please see notes below for each registration category.

1. Members of scientific societies that have endorsed and/or sponsored the Congress are eligible for a registration discount of \$100 off the regular rate. Multiple memberships cannot be combined to increase the discount. To view a list of these organizations, please visit <http://wcidt.org/endorsing-societies/>. Proof of membership includes a letter from the society or a membership ID card

Please note that the Endorsing Society Membership discount only applies to physicians and scientists, who have a current membership. The \$100 discount is already included in the Endorsing Society Member rate.

2. Medical Students/Residents: Proof of student status includes a letter from your department head or a copy of your student ID.

3. Allied Health Professionals are employed in the healthcare field, such as nurses, dietitians, nutritionists, etc. (not MDs, PhDs, MDs/PhDs or DOs). Proof of status includes a copy of your license, business card, or other proof of your position.

Payment Information

(Payment must accompany registration form in order to be processed.)

Bank Check payable in US funds to “Giovanni Lorenzini Medical Foundation--WCIDT” (see address below to mail payment)

VISA MasterCard American Express Discover

Card Number _____

Card ID Code _____

Expiration Date _____

Billing Address (if different from above) _____

Cancellation/Refund Policy:

Written requests for Cancellations must be submitted by 5:00 PM Eastern Time (GMT -4) February 28, 2011 to be considered. There will be a 30% processing fee for all refunds. Refunds will not be processed until after the meeting. Refund requests after 5:00 PM Eastern time (GMT -4) February 28, 2011 will not be honored; however, those registrants will receive the scientific matter after the meeting. Substitutions after March 18, 2011 will be charged a \$30.00 processing fee.

Send Cancellation/Refund Requests by:

Fax: +1 303 530 2691


Email: Gigi Andrew

gandrew@executiveevents.com

Mail: WCIDT Registration Center
c/o Executive Events
4665 Nautilus Court, Suite 502
Boulder, CO 80301 USA

For more information regarding the Congress and accommodations, please see the WCIDT website, www.wcidt.org
Questions regarding registration, contact Gigi Andrew, gandrew@executiveevents.com or call +1 303 530 0205 ext. 17
Question regarding the WCIDT Congress, contact wcidt@gomeeting.com or call +1 410 517 0590

Date _____ Signature _____



2ND WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES

VISIONARY LEVEL SUPPORTER




مؤسسة قطر
Qatar Foundation

إطلاق قدرات الإنسان.
Unlocking human potential.

CORPORATE SPONSORS

PLATINUM LEVEL



Ethicon
Endo-Surgery

PART OF THE Johnson & Johnson FAMILY OF COMPANIES

GOLD LEVEL



SILVER LEVEL



Medtronic

Alleviating Pain · Restoring Health · Extending Life


BRONZE LEVEL



WE WOULD ALSO LIKE TO THANK



MetaCure



2ND WORLD CONGRESS ON
INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES

www.wcidt.org

Giovanni Lorenzini Medical Foundation
6535 Fannin, MS A-601
Suite A754
Houston, TX 77030
Tel: +1 713 797 0401 • Fax: +1 713 796 8853